24 Oct 2008
Herceptin Decision Criticised
National's decision to fund 12 months of the breast cancer drug herceptin is criticised as undermining Pharmac's independence.
National's decision to fund 12 months of the breast cancer drug herceptin is criticised as undermining Pharmac's independence.